James Armitage, M.D.
The Joe Shapiro Professor of Medicine
Section of Oncology/Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Past President ASCO

Dr. James Armitage has served as Chair of Internal Medicine, Dean of the College of Medicine at Nebraska and currently is the Joe Shapiro Professor of Medicine in the section of Oncology/Hematology. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, a Fellow of both the American and Royal College of Physicians, a member of the National Cancer Advisory Board, and past president of both the American Society of Clinical Oncology and the American Society of Blood and Marrow Transplantation.

Joseph Bertino, M.D.
Associate Director and Chief Scientific Officer
Cancer Institute of New Jersey
University Professor UMDNJ-RWJMS
Past President AACR
Past President ASCO

Dr. Joseph Bertino is currently Associate Director and Chief Scientific Officer of the Cancer Institute of New Jersey and University Professor of Medicine and Pharmacology at UMDNJ-Robert Wood Johnson. Prior to his current position Dr. Bertino was Chairman of the Program of Molecular Pharmacology and Therapeutics at Memorial Sloan-Kettering Cancer Center and Professor of Medicine and Pharmacology at Cornell University Medical College. He spent many years at Yale University both as a Professor, Chief of Oncology and Chemotherapy and as the first Director of the Yale Comprehensive Cancer Center. Dr. Bertino is a past President of both the American Association for Cancer Research and the American Society of Clinical Oncology .

George Demetri, M.D.
Director, Center for Sarcoma and Bone Oncology
Senior Vice President for Experimental Therapeutics
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School

Dr. George Demetri is currently the Director of the Center for Sarcoma and Bone Oncology and Senior Vice President for Experimental Therapeutics at Dana-Farber Cancer Institute and Associate Professor of Medicine, Harvard Medical School. He led the clinical development and regulatory approval of Gleevec® for its indication of (GIST) gastrointestinal stromal tumor. Dr. Demetri's laboratory and clinical research focus is on the translation and clinical development of additional molecular-targeted agents in solid tumors .

Lawrence Einhorn, M.D.
Distinguished Professor of Medicine
Indiana University Simon Cancer Center
Lance Armstrong Professor of Oncology
Past President ASCO

Dr. Lawrence Einhorn is Distinguished Professor of Medicine, Section of Hematology/Oncology, Indiana University Simon Cancer Center and Lance Armstrong Professor of Oncology. He is a pioneer in combination chemotherapy, especially for testes cancer, where his work represents one of the most striking advances in cancer therapy. He has received many awards including the Kettering Prize in Cancer Research. He is Associate Editor for Medical and Pediatric Oncology, and Investigational New Drugs. Dr. Einhorn is a member of the National Academy of Sciences and past president of the American Society of Clinical Oncology

Alan Houghton, M.D.
Vice-Chair for Academic Affairs
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Virginia and Daniel K. Ludwig Clinical Chair


Dr. Houghton holds the Ludwig Chair in Clinical Investigation, and is Vice-Chair for Academic Affairs, Department of Medicine, Co-Head of the Melanoma Disease Management Team, and Head of the Laboratory of Tumor Immunology at Memorial Sloan-Kettering Cancer Center. He was the Chairman of Immunology at Sloan-Kettering and The Weill Graduate School of Biomedical Sciences of Cornell University (Sloan-Kettering Division) for 10 years, stepping down in 2004, and currently is a Professor of Medicine and Immunology at the Weill Medical and Graduate Schools of Cornell. He is also Chairman of the National Cancer Center Networks Melanoma Committee and Co-Chairman of the CALGB Melanoma Study Group of the national cooperative clinical trials group. Dr. Houghton was the first to demonstrate effectiveness of monoclonal antibody treatment for solid tumors and his laboratory has identified molecules and molecular targets on cancer cells that may be useful for therapy, many of which are currently being evaluated in clinical trials.

Alberto Pappo, M.D.
Member
Director-Solid Tumor Division
Department of Oncology
St Jude Children's Research Hospital

Dr. Alberto Pappo is a Member and Director of the solid malignancies program at St Jude Hospital in Memphis, Tennessee. Dr. Pappo is world-renowned in the basic and clinical research of rare cancers and sarcomas, especially in the pediatric setting. He was Chair of the Rare Tumors Committee of the Children's Oncology Group. In his role as committee chair, Dr. Pappo has been instrumental in drug development and novel clinical trial designs for rare cancers and pediatric sarcomas .

John F. Smyth, M.D.
Emeritus Professor of Medical Oncology
Assistant Principal
University of Edinburgh Medical School
Past President ECCO, Past President ESMO

Dr. John Smyth is Emeritus Professor of Medical Oncology, Assistant Principal, University of Edinburgh. His major research interest is the development and evaluation of new anti-cancer drugs. He is President of the Federation of European Cancer Societies and past President of both the European Cancer Organization and the European Society of Medical Oncology. He has published over 300 papers and is Editor-in-Chief of the European Journal of Cancer. He currently serves on the Expert Oncology Advisory Groups to the UK and European Drug Licensing Boards, and is a fellow of the Royal College of Physicians of Edinburgh and London, and fellow of the Royal Society of Edinburgh .

David Spriggs, M.D.
Head, Division of Solid Tumor Oncology
Memorial Sloan-Kettering Cancer Center
Winthrop Rockefeller Chair of Medical Oncology

David Spriggs, MD, is currently Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He is the Winthrop Rockefeller Professor in Medical Oncology. He is an internationally known solid-tumor oncologist whose research focuses on the genetic regulation of drug resistance and new chemotherapy regimens. Dr. Spriggs is a physician-investigator in charge of translational research - linking clinical and laboratory observations together to better understand cancer and improve cancer treatment .